Arsenite regulates cystic fibrosis transmembrane conductance regulator and P-glycoprotein: Evidence of pathway independence

Cellular Physiology and Biochemistry

Volumn 16, Issue 1-3, 2005, Pages 109-118

  Maitra, Rangan ^a,b   Hamilton, Joshua W ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b Icoria

Author keywords

Arsenite; CFTR; MAPK; P glycoprotein; Transcription

Indexed keywords

ARSENIC TRIOXIDE; GLYCOPROTEIN P; MITOGEN ACTIVATED PROTEIN KINASE; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

EID: 23944454848     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087737     Document Type: Article

References (42)

1. Roepe PD, Wei LY, Hoffman MM, Fritz F: Altered drug translocation mediated by the MDR protein: direct, indirect, or both? J Bioenerg Biomembr 1996;28:541-555.
2. Sheppard DN, Welsh MJ: Structure and function of the CFTR chloride channel. Physiological Reviews 1999;79:S23-45.
3. Zielenski J, Tsui LC: Cystic fibrosis: genotypic and phenotypic variations. Annu Rev Genet 1995;29:777-807.
4. Roninson IB: The role of the MDR1 (P-glycoprotein) gene in multidrug resistance in vitro and in vivo. Biochem Pharmacol 1992;43:95-102.
5. Broeks A, Gerrard B, Allikmets R, Dean M, Plasterk RH: Homologues of the human multidrug resistance genes MRP and MDR contribute to heavy metal resistance in the soil nematode Caenorhabditis elegans. EMBO J 1996;15:6132-6143.
6. Bates SE, Currier SJ, Alvarez M, Fojo AT: Modulation of P-glycoprotein phosphorylation and drug transport by sodium butyrate. Biochemistry 1992;31:6366-6372.
7. Ohga T, Uchiumi T, Makino Y, Koike K, Wada M, Kuwano M, Kohno K: Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene. J Biol Chem 1998;273:5997-6000.
8. Breuer W, Slotki IN, Ausiello DA, Cabantchik IZ: Induction of multidrug resistance downregulates the expression of CFTR in colon epithelial cells. Am J Physiol 1993;265:C1711-1715.
9. Trezise AE, Romano PR, Gill DR, Hyde SC, Sepulveda FV, Buchwald M, Higgins CF: The multidrug resistance and cystic fibrosis genes have complementary patterns of epithelial expression. EMBO J 1992;11:4291-4303.
10. Trezise AE, Ratcliff R, Hawkins TE, Evans MJ, Freeman TC, Romano PR, Higgins CF, Colledge WH: Co-ordinate regulation of the cystic fibrosis and multidrug resistance genes in cystic fibrosis knockout mice. Hum Mol Genet 1997;6:527-537.
11. Johannesson M, Nordqvist AC, Bogdanovic N, Hjelte L, Schalling M: Polymorphic expression of multidrug resistance mRNA in lung parenchyma of nonpregnant and pregnant rats: a comparison to cystic fibrosis mRNA expression. Biochem Biophys Res Commun 1997;239:606-611.
12. Lallemand JY, Stoven V, Annereau JP, Boucher J, Blanquet S, Barthe J, Lenoir G: Induction by antitumoral drugs of proteins that functionally complement CFTR: a novel therapy for cystic fibrosis? Lancet 1997;350:711-712.
13. Wei LY, Stutts MJ, Hoffman MM, Roepe PD: Overexpression of the cystic fibrosis transmembrane conductance regulator in NIH 3T3 cells lowers membrane potential and intracellular pH and confers a multidrug resistance phenotype. Biophys J 1995; 69: 883-895
14. Shibata Y, Morita M, Fuwa K: Selenium and arsenic in biology: their chemical forms and biological functions. Adv Biophys 1992;28:31-80.
15. Costa M: Carcinogenic metals. Sci Prog 1998;81(Pt 4):329-339.
16. Zhang P: The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia. J Biol Regul Homeost Agents 1999;13:195-200.
17. Kim SH, Yeo GS, Lim YS, Kang CD, Kim CM, Chung BS: Suppression of multidrug resistance via inhibition of heat shock factor by quercetin in MDR cells. Exp Mol Med 1998;30:87-92
18. Vilaboa NE, Galan A, Troyano A, de Blas E, Aller P: Regulation of multidrug resistance 1 (MDR1)/P-glycoprotein gene expression and activity by heat-shock transcription factor 1 (HSF1). J Biol Chem 2000;275:24970-24976
19. Xiong X, Bragin A, Widdicombe JH, Cohn J, Skach WR: Structural cues involved in endoplasmic reticulum degradation of G85E and G91R mutant cystic fibrosis transmembrane conductance regulator. J Clin Invest 1997;100:1079-1088.
20. Maitra R, Shaw CM, Stanton BA, Hamilton JW: Increased functional cell surface expression of CFTR and DeltaF508-CFTR by the anthracycline doxorubicin. Am J Physiol Cell Physiol 2001;280:C1031-C1037.
21. Kartner N, Riordan JR: Characterization of polyclonal and monoclonal antibodies to cystic fibrosis transmembrane conductance regulator. Methods in Enzymology 1998;292:629-652.
22. West MR, Molloy CR: A microplate assay measuring chloride ion channel activity. Anal Biochem 1996;241:51-58.
23. Yamaguchi Y, Wada T, Handa H: Interplay between positive and negative elongation factors: drawing a new view of DRB. Genes Cells 1998;3:9-15.
24. Kim SH, Lee SH, Kwak NH, Kang CD, Chung BS: Effect of the activated Raf protein kinase on the human multidrug resistance 1 (MDR1) gene promoter. Cancer Lett 1996;98:199-205.
25. Rohlff C, Glazer RI: Regulation of the MDR1 promoter by cyclic AMP-dependent protein kinase and transcription factor Sp1. Int J Oncol 1998;12:383-386.
26. Fischer H, Illek B, Machen TE: Regulation of CFTR by protein phosphatase 2B and protein kinase C. Pflugers Arch 1998;436:175-181.
27. Chao AC, de Sauvage FJ, Dong YJ, Wagner JA, Goeddel DV, Gardner P: Activation of intestinal CFTR Cl-channel by heat-stable enterotoxin and guanylin via cAMP-dependent protein kinase. EMBO J 1994;13:1065-1072.
28. Hidaka H, Hagiwara M, Chijiwa T: Molecular pharmacology of protein kinases. Neurochem Res 1990;15:431-434.
29. Chijiwa T, Mishima A, Hagiwara M, Sano M, Hayashi K, Inoue T, Naito K, Toshioka T, Hidaka H: Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5- isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J Biol Chem 1990;265:5267-5272.
30. Martiny-Baron G, Kazanietz MG, Mischak H, Blumberg PM, Kochs G, Hug H, Marme D, Schachtele C: Selective inhibition of protein kinase C isozymes by the indolocarbazole Go 6976. J Biol Chem 1993;268:9194-9197.
31. Bernstam L, Nriagu J: Molecular aspects of arsenic stress. J Toxicol Environ Health B Crit Rev 2000;3:293-322.
32. Ratner AJ, Bryan R, Weber A, Nguyen S, Barnes D, Pitt A, Gelber SE, Cheung, A, Prince A: Cystic fibrosis pathogens activate Ca{super2+}-dependent MAPK signaling pathways in airway epithelial cells. J Biol Chem 2001;276:19267-19275.
33. Wartenberg M, Ling FC, Schallenberg M, Baumer AT, Petrat K, Hescheler J, Sauer H: Down-regulation of intrinsic p-glycoprotein expression in multicellular prostate tumor spheroids by reactive oxygen species. J Biol Chem 2001;276:17420-17428.
34. Winston LA, Hunter T: Intracellular signalling: putting JAKs on the kinase MAP. Curr Biol 1996;6:668-671.
35. Barchowsky A, Roussel RR, Klei LR, James PE, Ganju N, Smith KR, Dudek EJ: Low levels of arsenic trioxide stimulate proliferative signals in primary vascular cells without activating stress effector pathways. Toxicol Appl Pharmacol 1999;159:65-75.
36. Chakraborti S, Chakraborti T: Oxidant-mediated activation of mitogen-activated protein kinases and nuclear transcription factors in the cardiovascular system: a brief overview. Cell Signal 1998;10:675-683.
37. Mylona P, Glazier JD, Greenwood SL, Sides MK, Sibley CP: Expression of the cystic fibrosis (CF) and multidrug resistance (MDR1) genes during development and differentiation in the human placenta. Mol Hum Reprod 1996;2:693-698.
38. Lau AT, Li M, Xie R, He QY, Chiu JF: Opposed arsenite-induced signaling pathways promote cell proliferation or apoptosis in cultured lung cells. Carcinogenesis 2004;25:21-28.
39. Sullivan LP, Wallace DP, Grantham JJ: Epithelial transport in polycystic kidney disease. Physiological Reviews 1998;78:1165-1191.
40. Persu A, Devuyst O, Lannoy N, Materne, R, Brosnahan G, Gabow PA, Pirson Y, Verellen-Dumoulin C: CF gene and cystic fibrosis transmembrane conductance regulator expression in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2000;11:2285-2296.
41. Kirk KL: New paradigms of CFTR chloride channel regulation. Cell Mol Life Sci 2000;57:623-634.
42. Akabas MH: Cystic fibrosis transmembrane conductance regulator. Structure and function of an epithelial chloride channel. J Biol Chem 2000;275:3729-3732.